share_log

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Shareholder Returns Have Been Solid, Earning 257% in 3 Years

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Shareholder Returns Have Been Solid, Earning 257% in 3 Years

通化金馬藥業股份有限公司(深交所代碼:000766)股東回報穩健,3年內收益爲257%
Simply Wall St ·  2023/11/12 20:30

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) shareholders have seen the share price descend 12% over the month. But that doesn't undermine the rather lovely longer-term return, if you measure over the last three years. In fact, the share price is up a full 257% compared to three years ago. It's not uncommon to see a share price retrace a bit, after a big gain. If the business can perform well for years to come, then the recent drop could be an opportunity.

通化金馬藥業股份有限公司(深圳證券交易所代碼:000766)的股東本月股價下跌了12%。但是,如果你衡量過去三年的情況,這並不能破壞相當可觀的長期回報。實際上,與三年前相比,股價上漲了整整257%。股價在大幅上漲之後略有回調的情況並不少見。如果業務能夠在未來幾年內表現良好,那麼最近的下跌可能是一個機會。

Since it's been a strong week for Tonghua Golden-Horse Pharmaceutical Industry CoLtd shareholders, let's have a look at trend of the longer term fundamentals.

由於對於通化金馬藥業股份有限公司股東來說,這是強勁的一週,讓我們來看看長期基本面的走勢。

Check out our latest analysis for Tonghua Golden-Horse Pharmaceutical Industry CoLtd

查看我們對通化金馬藥業有限公司的最新分析

Given that Tonghua Golden-Horse Pharmaceutical Industry CoLtd only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. It would be hard to believe in a more profitable future without growing revenues.

鑑於通化金馬藥業有限公司在過去十二個月中僅實現了最低收益,我們將重點關注收入來衡量其業務發展。通常,我們認爲這種公司更能與虧損股票相提並論,因爲實際利潤太低了。如果不增加收入,很難相信未來會有更有利可圖的未來。

In the last 3 years Tonghua Golden-Horse Pharmaceutical Industry CoLtd saw its revenue grow at 5.0% per year. That's not a very high growth rate considering it doesn't make profits. In comparison, the share price rise of 53% per year over the last three years is pretty impressive. We'd need to take a closer look at the revenue and profit trends to see whether the improvements might justify that sort of increase. It seems likely that the market is pretty optimistic about Tonghua Golden-Horse Pharmaceutical Industry CoLtd, given it is losing money.

在過去的3年中,通化金馬藥業有限公司的收入以每年5.0%的速度增長。考慮到它沒有盈利,這不是一個很高的增長率。相比之下,過去三年股價每年上漲53%,令人印象深刻。我們需要仔細研究收入和利潤趨勢,看看這些改善是否可以證明這種增長是合理的。鑑於通化金馬藥業有限公司正在虧損,市場似乎對通化金馬藥業有限公司相當樂觀。

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

公司的收入和收益(一段時間內)如下圖所示(點擊查看確切數字)。

earnings-and-revenue-growth
SZSE:000766 Earnings and Revenue Growth November 13th 2023
SZSE: 000766 2023年11月13日收益和收入增長

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在這張免費的交互式圖片中看到其資產負債表如何隨着時間的推移而增強(或減弱)。

A Different Perspective

不同的視角

It's nice to see that Tonghua Golden-Horse Pharmaceutical Industry CoLtd shareholders have received a total shareholder return of 136% over the last year. That's better than the annualised return of 10% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Tonghua Golden-Horse Pharmaceutical Industry CoLtd you should know about.

很高興看到通化金馬藥業有限公司的股東在過去一年中獲得了136%的總股東回報率。這比五年來10%的年化回報率要好,這意味着該公司最近的表現更好。在最好的情況下,這可能暗示着一些真正的業務勢頭,這意味着現在可能是深入研究的好時機。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,考慮風險。每家公司都有它們,我們發現了兩個你應該知道的通化金馬藥業有限公司的警告標誌。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想和管理層一起購買股票,那麼你可能會喜歡這份免費的公司清單。(提示:內部人士一直在買入它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論